search
Back to results

A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury

Primary Purpose

Rectal Injury

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TH-SC01(Umbilical cord mesenchymal stem cells)
Sponsored by
Jinling hospital Nanjing, Jiangsu, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rectal Injury

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Fully understand and sign the informed consent form; Age ≥18 years and <80 years; Patients diagnosed with chronic radiation rectal injury after radiation therapy; Patients with LENT-SOMA scale score ≥1; Good physical condition (WHO functional status score 0-1). Exclusion Criteria: The patient had severe liver and kidney disease; Severe congestive heart failure or coronary heart disease; Patients have allergic constitutions or severe systemic immune diseases; The patient had active gastrointestinal hemorrhage or acute intestinal obstruction; Patients were pregnant or had other conditions that the investigators deemed unsuitable for inclusion in the study.

Sites / Locations

  • Jinling Hospital, ChinaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TH-SC01 local injection treatment group

Arm Description

The trial was conducted in a non-randomized, single-center, single-arm, dose-escalation design. Three dose groups were preset, which were as follows: Low dose group: 3×10^7 live cells/person (6mL); Medium dose group: 6×10^7 live cells/person (12mL) ; High dose group: 1.2×10^8 live cells/person (24mL); Each subject should receive only one corresponding dose. Three subjects were enrolled in the low-dose group,If the safety of the subjects was good, the researchers evaluated the safety and efficacy data and entered the next dose group for treatment. The medium and high-dose groups were enrolled according to the "5+7" principle. For the first 3 dose groups, after safety evaluation by the investigators, the maximum dose could reach 2.4×10^8 live cells/person (48mL). If the MTD group is not identified by the highest dose group, it is up to the investigator to decide whether to continue with dose escalation.

Outcomes

Primary Outcome Measures

lentsoma score scale improved > 0.6 points
lentsoma scale can comprehensively reflect the severity of radiation-induced rectal injury from three aspects: subjective feeling, objective situation and intervention measures. There are 14 items in total, each item has a maximum of 4 points, and the final total is divided by 14.

Secondary Outcome Measures

The decreasing level of the Rectal Telangiectasia Density Scale(RTD)
The degree of capillary dilatation at the lesion site was observed during colonoscopy. There were four grades, with the highest score being 3.
The declining level of the Vienna Rectoscopy Score
The Vienna Rectoscopy Score evaluated the severity of the disease under colonoscopy in five aspects: the degree of telangiectasia, mucosal congestion, ulceration, stenosis, and necrosis. The most serious score is 5 points.
The decreased level ofSemi-quantitative Score of Rectal Radiological Pathological Injury
The histological severity of the rectal injury was assessed by colonoscopy. The most severe rating is 10
The decreased levels of SF-36 Scale
The quality of life of patients before and after treatment
The decreased levels of Hospital Anxiety and Depression Scales
To assess the level of anxiety and depression in the subjects in the hospital
The decreased levels of Visual Analogue Pain Rating Scale
The degree of pain is represented by a total of 11 numbers from 0 to 10, 0 means no pain, 10 represents the most pain, according to the degree of pain in the 11 numbers to select a number to represent the pain degree.
Serious adverse event occurred
Cases such as fever, allergy, pain, and severe bleeding should be recorded immediately and treated actively

Full Information

First Posted
July 2, 2023
Last Updated
July 10, 2023
Sponsor
Jinling hospital Nanjing, Jiangsu, China
Collaborators
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05939778
Brief Title
A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury
Official Title
A Study on the Efficacy and Safety of Endoscopic Local Injection of Umbilical Cord Mesenchymal Stem Cells(TH-SC01) for the Treatment of Radiation-induced Rectal Injury.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 21, 2022 (Actual)
Primary Completion Date
January 21, 2024 (Anticipated)
Study Completion Date
January 21, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jinling hospital Nanjing, Jiangsu, China
Collaborators
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy and safety of allogeneic umbilical cord mesenchymal stem cells in the treatment of radiation-induced rectal injury.
Detailed Description
radiation-induced rectal injury (RRI) is a common clinical disease. The symptoms of RRI often include: Abdominal pain, diarrhea, hematochezia, etc., especially chronic radiation-induced late rectal injury (RLRI), are easy to cause the disease to prolong and not heal. Some patients will have severe complications such as massive rectal bleeding, rectal stenosis, intestinal obstruction, deep ulcer, intestinal perforation, and fistula formation after the disease progresses to the advanced stage, most of which occur 2-5 years after the end of radiotherapy. The incidence of radiation rectal injury is high, which has a serious impact on the health and quality of life of patients. Currently, the commonly used treatment methods include non-steroidal anti-inflammatory drugs, mucosal protective agents, hemostatic agents, compound enema preparations, hyperbaric oxygen, surgical treatment, etc., but there is still no standard treatment strategy and effective plan, and clinical treatment is extremely difficult. Mesenchymal stem cells have the properties of proliferation, differentiation, immune regulation and angiogenesis. There are few clinical studies on the use of mesenchymal stem cells in the treatment of radiation-induced rectal injury. Good therapeutic effect was achieved in vivo and in vitro in the preliminary experiment. The aim of this study was to verify the safety and efficacy of allogeneic mesenchymal stem cells from healthy donors in RRI patients. Primary objective: To assess the safety (incidence of treatment emergent adverse-events) of TH-SC01.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TH-SC01 local injection treatment group
Arm Type
Experimental
Arm Description
The trial was conducted in a non-randomized, single-center, single-arm, dose-escalation design. Three dose groups were preset, which were as follows: Low dose group: 3×10^7 live cells/person (6mL); Medium dose group: 6×10^7 live cells/person (12mL) ; High dose group: 1.2×10^8 live cells/person (24mL); Each subject should receive only one corresponding dose. Three subjects were enrolled in the low-dose group,If the safety of the subjects was good, the researchers evaluated the safety and efficacy data and entered the next dose group for treatment. The medium and high-dose groups were enrolled according to the "5+7" principle. For the first 3 dose groups, after safety evaluation by the investigators, the maximum dose could reach 2.4×10^8 live cells/person (48mL). If the MTD group is not identified by the highest dose group, it is up to the investigator to decide whether to continue with dose escalation.
Intervention Type
Biological
Intervention Name(s)
TH-SC01(Umbilical cord mesenchymal stem cells)
Intervention Description
"5+7" principle: 1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step. 2. 7 subjects were included in the second step.
Primary Outcome Measure Information:
Title
lentsoma score scale improved > 0.6 points
Description
lentsoma scale can comprehensively reflect the severity of radiation-induced rectal injury from three aspects: subjective feeling, objective situation and intervention measures. There are 14 items in total, each item has a maximum of 4 points, and the final total is divided by 14.
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
The decreasing level of the Rectal Telangiectasia Density Scale(RTD)
Description
The degree of capillary dilatation at the lesion site was observed during colonoscopy. There were four grades, with the highest score being 3.
Time Frame
16 weeks
Title
The declining level of the Vienna Rectoscopy Score
Description
The Vienna Rectoscopy Score evaluated the severity of the disease under colonoscopy in five aspects: the degree of telangiectasia, mucosal congestion, ulceration, stenosis, and necrosis. The most serious score is 5 points.
Time Frame
16 weeks
Title
The decreased level ofSemi-quantitative Score of Rectal Radiological Pathological Injury
Description
The histological severity of the rectal injury was assessed by colonoscopy. The most severe rating is 10
Time Frame
16 weeks
Title
The decreased levels of SF-36 Scale
Description
The quality of life of patients before and after treatment
Time Frame
16 weeks
Title
The decreased levels of Hospital Anxiety and Depression Scales
Description
To assess the level of anxiety and depression in the subjects in the hospital
Time Frame
16 weeks
Title
The decreased levels of Visual Analogue Pain Rating Scale
Description
The degree of pain is represented by a total of 11 numbers from 0 to 10, 0 means no pain, 10 represents the most pain, according to the degree of pain in the 11 numbers to select a number to represent the pain degree.
Time Frame
16 weeks
Title
Serious adverse event occurred
Description
Cases such as fever, allergy, pain, and severe bleeding should be recorded immediately and treated actively
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Fully understand and sign the informed consent form; Age ≥18 years and <80 years; Patients diagnosed with chronic radiation rectal injury after radiation therapy; Patients with LENT-SOMA scale score ≥1; Good physical condition (WHO functional status score 0-1). Exclusion Criteria: The patient had severe liver and kidney disease; Severe congestive heart failure or coronary heart disease; Patients have allergic constitutions or severe systemic immune diseases; The patient had active gastrointestinal hemorrhage or acute intestinal obstruction; Patients were pregnant or had other conditions that the investigators deemed unsuitable for inclusion in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fangyu Wang
Phone
0086-13515100636
Email
quanguorenmin1994@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Haoyu Xu
Phone
0086-17362954983
Email
quanguorenmin1994@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fangyu Wang
Organizational Affiliation
Director of gastroenterology Department, Jinling Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Jinling Hospital, China
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fangyu Wang
Phone
0086-13515100636
Email
quanguorenmin1994@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury

We'll reach out to this number within 24 hrs